After a disappointing two months, Emergent Biosolutions declared on Monday, January 7th, 2007 that it expected to report an increase in sales of up to 20% from 2006, above what it predicted earlier in the year. According to Emergent, 2007 revenue was approximately $183 million. Emergent forecasts even higher revenues in 2008 due to its recent contract selling 19 million more doses of BioThrax to the U.S. government. This news caused its stock price to rise as much as 60%, up to nearly $8.00 per share. Source: Baltimore Business Journal 01/07/2008
After a disappointing two months, Emergent Biosolutions declared on Monday, January 7th, 2007 that it expected to report an increase in sales of up to 20% from 2006, above what it predicted earlier in the year. According to Emergent, 2007 revenue was approximately $183 million, and even higher revenues are forecasted in 2008. This news caused its stock price to rise as much as 60%, up to nearly $8.00 per share.Baltimore Business Journal, 01/07/2008, http://www.bizjournals.com/baltimore/stories/2008/01/07/daily4.html?ana=from_rss
On November 2nd, Emergent announced that its profits had fallen by 35% in the Third Quarter due to greater costs of sale for BioThrax. Earnings per share was only 10 cents, down from 18 cents a year prior. This disappointing announcement led to a fall in the stock price of about 50%.
